Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Advisory

IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry


IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, announced today it will deliver an oral presentation during the upcoming XXVII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC). The symposium will take place in Nice, France, from September 4-8, 2022.

"New therapeutics for the treatment of neurodevelopmental disorders are urgently needed. I am humbled to reveal our approach targeting brain chloride homeostasis to treat such disorders at the EFMC-ISMC 2022," said Marco Borgogno, Ph.D. Team Leader in Discovery Chemistry at IAMA Therapeutics. "In this upcoming presentation, I will present our advances in developing novel selective NKCC1 inhibitors toward novel sustainable treatments for these unmet medical needs."

"We are excited and honored to have our data on a class of selective NKCC1-inhibitors selected for an oral presentation at EFMC-ISMC 2022, which demonstrates that our multi-program pipeline of drug candidates achieved important results across the lead optimization programs and preclinical phases," said Andrea P. Malizia, Chief Executive Officer of IAMA Therapeutics. "The presented data further expands upon the neuroscience drug discovery initiative, which identifies therapeutic opportunities for individuals suffering from neurodevelopmental and cognitive disorders."

Details of the oral presentation are as follows:
Title: Discovery of selective NKCC1 inhibitors for the treatment of core symptoms in Autism, Down syndrome, and brain disorders with defective NKCC1/KCC2 ratio.
Presenter: Marco Borgogno Ph.D., Team Leader in Discovery Chemistry, IAMA Therapeutics.
Session Type/Title: Drug Discovery in Targeting Neurodegenerative Disorders, in collaboration with the Medicinal Chemistry Division of the American Chemical Society (ACSMEDI).
Date and time: Thursday, September 8, 2022, 11:30 AM-11:50 AM (CET)

About IAMA-6
IAMA-6 is a preclinical stage, a first-in-class selective-NKCC1 inhibitor that modulates the intracellular chloride, reducing the depolarizing strength of GABAA receptors to the levels required to restore the inhibitory transmission. This pathway is reported in Down syndrome, autism spectrum disorder, epilepsy, and other brain disorders characterized by increased intracellular chloride and depolarizing GABAergic transmission.
IAMA Therapeutics acquired rights to IAMA-6 and a class of selective NKCC1-inhibitors through a licensing with the Italian Institute of Technology (IIT).

About IAMA Therapeutics
IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a difference in the lives of children and adults suffering from neurodevelopmental and cognitive disorders. IAMA Therapeutics couples emerging advances in drug discovery and neurobiology to build a leading, next-generation neuroscience pipeline to selectively inhibit the sodium-potassium chloride cotransporter and other therapeutic targets relevant to brain disorders characterized by neuronal imbalance.
The company's preclinical pipeline consists of the lead candidate IAMA-6 for the treatment of idiopathic autism, IAMA-097 for the treatment of secondary autism, and other compounds for the treatment of refractory epilepsy and other brain disorders.


These press releases may also interest you

at 20:37
In advance of the July 4th Independence Day weekend, the American Association of Kidney Patients (AAKP), the nation's largest independent kidney patient organization, released their annual summer reading list featuring articles by AAKP-affiliated...

at 20:20
From a cold, wet spring that forced a late planting to June storms that left many Midwestern farmers assessing hail damage, the 2022 growing season got off to a bumpy start across much of the Corn Belt. Fortunately, farmers are resilient by nature,...

at 20:13
Carebook Technologies Inc. ("Carebook" or the "Company") (XETR: PMM1), a leading Canadian provider of innovative digital health solutions, today announced the voting results from the Annual General and Special Meeting of its Shareholders held...

at 19:23
Pharmacy benefit manager (PBM) Prime Therapeutics' proposed acquisition of rival PBM Magellan Rx Management "raises serious anti-competitive concerns" and should be blocked, according to a letter sent today from American Pharmacy Cooperative, Inc....

at 19:08
BIOLASE, Inc. , the global leader in dental lasers, announced that, on June 30, 2022, it entered into an amendment to its senior secured term loan with SWK Funding LLC. The amendment extends the interest-only period of the loan by two quarters to...

at 19:04
NVISION® Eye Centers is pleased to announce the addition of two retina practices to the NVISION family ? Salt Lake Retina in Salt Lake City, UT and Retina Associates of Southern California in Los Angeles and Orange County, California....



News published on 24 may 2022 at 07:35 and distributed by: